University of Cambridge
The University of Cambridge, founded in 1209, is a prestigious public research university located in Cambridge, United Kingdom. It is organized into 31 colleges and 150 departments, encompassing six schools: Arts and Humanities, Biological Sciences, Clinical Medicine, Humanities and Social Sciences, Physical Sciences, and Technology. With a diverse community of over 20,000 students and 12,000 staff members from around the globe, the university offers a wide range of undergraduate, graduate, and postgraduate programs across various disciplines, including humanities, sciences, law, and engineering. In addition to its educational offerings, the university is renowned for its extensive research activities, which span fields such as clinical medicine, biomedicine, and engineering. The institution also manages museums, libraries, and collections, and actively commercializes intellectual properties developed within its academic framework. The University of Cambridge is recognized as one of the world's leading academic institutions, noted for its historical significance, outstanding academic achievements, and contributions to research and knowledge.
Top Stages
113 past transactions
Robin AI
Series B in 2024
Robin AI is a legal technology startup focused on automating legal processes through artificial intelligence. Its software enhances the contract mark-up process by providing essential features while ensuring enterprise-grade encryption and security, which helps safeguard sensitive data. The platform empowers legal teams to delegate low-complexity tasks, thereby simplifying and streamlining legal workflows. By automating routine aspects of legal work, Robin AI enables professionals to concentrate on more complex and high-value tasks, ultimately improving productivity and efficiency within legal practices.
Xwatts
Pre Seed Round in 2024
Xwatts is a developer of an intelligent energy management system specifically designed for commercial buildings. The company focuses on reducing costs and emissions through continuous analysis of energy usage patterns, environmental conditions, and market data. By optimizing and automating electricity consumption, Xwatts enables building owners to take direct control of their distributed energy assets. The system evaluates historical usage alongside real-time market data to enhance asset scheduling and minimize electricity consumption costs, thereby promoting more efficient energy management in commercial properties.
Wave Photonics
Seed Round in 2024
Wave Photonics is a company based in Cambridge, UK, focused on enhancing the design and integration of integrated photonics products. It develops a platform that utilizes computational techniques to optimize product designs and streamline the supply chain. This platform offers a software tool that predicts the performance and variability of components based on specific fabrication processes, along with an optimizer to create a library of foundry-specific components. By facilitating the development and mass production of integrated photonics technologies, Wave Photonics aims to improve efficiency and reduce redundancy for businesses in the sector.
Echion Technologies
Series B in 2024
Echion Technologies, founded in 2017 and based in Cambridge, United Kingdom, specializes in developing advanced anode materials for lithium-ion (Li-ion) batteries. Their proprietary XNO® material offers faster charging times, longer lifespans, and improved safety compared to traditional options. The company targets the heavy-duty electric vehicle market, aiming to enhance efficiency and sustainability within the transportation sector by providing optimized power anode materials for cost-effective battery production.
Zetta Genomics
Seed Round in 2024
Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.
Xampla
Series B in 2024
Founded in 2018, Xampla develops plant-based materials derived from pea protein to replace microplastics. Its product range includes microcapsules for homecare and personal care products, films, coatings, and single-use plastics for packaging applications.
T-Therapeutics
Series A in 2023
T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.
Nu Quantum
Seed Round in 2023
Nu Quantum Ltd is a company focused on developing quantum photonics hardware and quantum networking infrastructure to enhance the capabilities of quantum computing. Established in 2018 and based in Cambridge, United Kingdom, the company specializes in creating photon sources, detectors, and systems for quantum cryptography. Nu Quantum's innovations include nano-engineered materials for the generation of light at the quantum level and ultra-sensitive light detection systems. The company aims to establish the necessary infrastructure for interconnecting quantum computing cores into large distributed clusters, which is essential for scaling quantum computers. By developing full hardware solutions, including high-speed network interfaces and photonic switching fabrics, Nu Quantum seeks to facilitate the creation of entangled qubit networks. The company collaborates with leading quantum computing firms, governments, and research institutions to bring its advanced technologies to market, focusing on secure cryptographic key exchange and the future of information processing.
Materials Nexus
Seed Round in 2023
Materials Nexus is a deep-tech company specializing in automated quantum calculations for accurate large-scale material analysis. They aim to accelerate the development of sustainable materials and reduce CO2 emissions.
RoboK
Seed Round in 2023
RoboK develops innovative computer vision technology to enhance safety and efficiency in industrial workplaces. Founded in 2017, the company transforms on-site visual data from CCTV cameras into valuable actionable insights for critical infrastructure operators.
Planetary Processing
Pre Seed Round in 2023
Planetary Processing is a technology company that specializes in providing a Software Development Kit (SDK) for the creation and operation of massively-multiplayer online games. Their platform simplifies the process of building and maintaining large-scale online games, allowing game studios to concentrate on game development rather than infrastructure. They cater to small and medium game studios, offering a software-as-a-service hosting platform that facilitates a toolkit for creating and running large-scale multiplayer games from scratch, using the game engine of choice. The platform handles network coding and server hosting, enabling game developers to focus on building their game.
PharmEnable
Seed Round in 2023
PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that specializes in the design of small molecule drugs through the integration of medicinal chemistry and artificial intelligence computational methods. Established in 2016, the company has created a rapid and cost-effective approach to identify superior chemical starting points, thereby facilitating the discovery of essential new medicines.
Zetta Genomics
Seed Round in 2023
Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.
Seprify
Seed Round in 2023
Seprify develops and sells cellulose-based white pigments and opacifiers, aiming to replace titanium dioxide in various industries. Their plant-derived solutions are renewable, biocompatible, and scalable, promoting sustainability and safety in product manufacturing.
52 North Health
Seed Round in 2023
52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.
Kalium Health
Venture Round in 2022
Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.
Carbon Re
Seed Round in 2022
Carbon Re is a climate technology company specializing in artificial intelligence for industrial decarbonization. It focuses on energy-intensive sectors like cement, steel, and glass, which contribute over 20% of global emissions. Carbon Re's Delta Zero platform uses deep learning to rapidly develop and deploy new low-carbon processes, designs, and materials.
Pretzel Therapeutics
Series A in 2022
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.
CardiaTec Biosciences
Pre Seed Round in 2022
CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.
Spirea
Venture Round in 2022
Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.
Colorifix
Series B in 2022
Colorifix is a biotechnology company that pioneers biological methods for textile dyeing. It converts agricultural by-products into colorants suitable for textiles, eliminating harsh chemicals and significantly reducing water consumption.
Concr
Seed Round in 2022
Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.
52 North Health
Seed Round in 2022
52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.
Regulatory Genome
Seed Round in 2022
Regulatory Genome provides dynamic, granular, and interoperable machine-readable regulatory content powered by AI-based textual information extraction techniques. Regulatory Genome enables regulatory authorities to improve the accessibility and dissemination of regulatory information, while also enabling organizations to deepen their regulatory intelligence and digitize their compliance and risk management processes. RegGenome content is vendor-neutral, allowing it to be integrated into any application or system, allowing for the creation of an efficient ecosystem of providers and users.
Tenyks
Seed Round in 2022
Tenyks is a Cambridge University spin-out developing an MLOps monitoring and validation platform for computer vision data. It helps machine learning engineers understand and fix algorithm issues, enhancing software reliability.
BKwai
Seed Round in 2022
BKwai delivers insights to engineers by combining research, applied technology, and data from on-site sensors and satellite imagery to support a more resilient built environment. The company has developed a software platform that enhances infrastructure asset management across the lifecycle by applying artificial intelligence and structural engineering expertise to monitor the structural health of infrastructure and its surroundings, enabling safer, smarter, and more efficient operations. Its goal is to unlock the full potential of site data to transform construction and asset management.
Semarion
Seed Round in 2022
Semarion is a Cambridge-based company that combines microchip industry materials engineering with cell biology. It aims to revolutionize drug discovery by developing a platform that uses ultra-miniaturized, magnetically steerable wells for adherent cell screening.
Signaloid
Pre Seed Round in 2022
Signaloid is a technology company that specializes in computing platforms and software solutions aimed at uncertainty-tracking in data inputs. Its offerings include a cloud platform and application programming interface that facilitate advanced computations and data storage. The company's technologies are applicable across various fields such as materials modeling, autonomous systems, computational finance, machine learning, and quantum computing. By leveraging its innovations, Signaloid enables clients to assess the impact of uncertainties on their decision-making processes, helping them to ensure compliance with regulations, optimize costs, and enhance safety outcomes.
Barocal
Seed Round in 2022
Barocal develops innovative cooling technology designed to meet low-carbon refrigeration needs. Its proprietary materials undergo significant thermal changes under pressure application and removal, enhancing energy efficiency and eliminating greenhouse gas warming impact in commercial food and drink refrigeration.
Zetta Genomics
Seed Round in 2022
Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.
Carbon Re
Pre Seed Round in 2021
Carbon Re is a climate technology company specializing in artificial intelligence for industrial decarbonization. It focuses on energy-intensive sectors like cement, steel, and glass, which contribute over 20% of global emissions. Carbon Re's Delta Zero platform uses deep learning to rapidly develop and deploy new low-carbon processes, designs, and materials.
Wave Photonics
Pre Seed Round in 2021
Wave Photonics is a company based in Cambridge, UK, focused on enhancing the design and integration of integrated photonics products. It develops a platform that utilizes computational techniques to optimize product designs and streamline the supply chain. This platform offers a software tool that predicts the performance and variability of components based on specific fabrication processes, along with an optimizer to create a library of foundry-specific components. By facilitating the development and mass production of integrated photonics technologies, Wave Photonics aims to improve efficiency and reduce redundancy for businesses in the sector.
Echion Technologies
Series A in 2021
Echion Technologies, founded in 2017 and based in Cambridge, United Kingdom, specializes in developing advanced anode materials for lithium-ion (Li-ion) batteries. Their proprietary XNO® material offers faster charging times, longer lifespans, and improved safety compared to traditional options. The company targets the heavy-duty electric vehicle market, aiming to enhance efficiency and sustainability within the transportation sector by providing optimized power anode materials for cost-effective battery production.
Porotech
Venture Round in 2021
Porotech is a Cambridge University spin-out focused on developing wide-bandgap compound gallium nitride (GaN) semiconductors. It aims to revolutionize the electronics industry by applying advanced material technologies to unlock GaN's full potential, enabling more efficient light-emitting diodes and other electronic devices.
Porotech
Seed Round in 2021
Porotech is a Cambridge University spin-out focused on developing wide-bandgap compound gallium nitride (GaN) semiconductors. It aims to revolutionize the electronics industry by applying advanced material technologies to unlock GaN's full potential, enabling more efficient light-emitting diodes and other electronic devices.
iKVA
Seed Round in 2021
iKVA develops AI-powered knowledge management software that enhances decision-making and organizational efficiency. Its platform employs advanced vector mapping technology, dark data discovery, and multilingual information retrieval to help businesses uncover hidden insights, reduce costs, and boost productivity.
Abselion
Seed Round in 2021
Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of biological substances such as proteins, DNA, and small molecules. The company focuses on simplifying the analysis of these biomolecules for pharmaceutical research and manufacturing. Its diagnostic analyzers and kits facilitate the analysis of biomolecular interactions, including protein interaction analysis, enabling researchers to achieve sensitive and timely medical diagnoses. Through its innovative technology, Abselion enhances the efficiency of biomedical research and contributes to advancements in medical diagnostics.
Concr
Pre Seed Round in 2021
Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.
Nyobolt
Series A in 2021
Founded in 2020, Nyobolt is a UK-based company specializing in advanced battery technology for automotive applications. It focuses on developing high-power, fast-charging batteries with large energy storage capacity.
Cambridge GaN Devices
Series A in 2021
Cambridge GaN Devices develops gallium nitride based power devices and transistors designed to improve energy efficiency in power electronics. The company designs, creates, and commercializes GaN-based semiconductors that achieve faster switching, lower energy losses, and smaller form factors compared with traditional silicon devices while delivering higher power density. Its products are intended for applications in sectors such as renewable energy, electric vehicles, and consumer electronics, enabling compact and more efficient power conversion and energy management. The company collaborates with industry partners to drive innovation and accelerate adoption of GaN technology in the power semiconductor market.
NiftPad
Pre Seed Round in 2021
NiftPad is a company that empowers brands to create and sell unique digital assets through its innovative white-label shop platform. Founded in October 2021 as a spin-off from the University of Cambridge, NiftPad provides a no-code application that allows enterprises to easily launch non-fungible token projects. This platform enables businesses to build fully customizable online stores for issuing and selling digital assets, facilitating new avenues for revenue generation and enhancing community engagement. Backed by notable investors, NiftPad aims to simplify the process of entering the digital asset market for various brands.
Sano Genetics
Seed Round in 2021
Sano Genetics is a health technology company that operates a user-centered genetic data-sharing platform. The platform enables researchers to analyze data provided with user consent and to recruit for studies and clinical trials based on participants’ genetic and health information. It provides access to research on genetics and genetic diseases and supports programs that study the genetics of various human traits. The company connects individuals with researchers through its platform, supporting both common and rare disease research and enabling dynamic, health and genetic data sets to advance personalized medicine. Founded in 2017 and based in Cambridge, United Kingdom, Sano Genetics aims to empower participants to contribute their genetic and health data to scientific studies, facilitating collaboration and enabling new approaches to diagnosis and treatment.
Riverlane
Series A in 2021
Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.
8power
Series A in 2020
8power Limited develops wireless sensor technology for industrial plant applications. Its systems monitor machine conditions across thousands of remote assets in sectors like automotive, civil engineering, and utilities.
Sorex Sensors
Seed Round in 2020
Sorex Sensors designs and manufactures high-sensitivity micro-electro-mechanical system (MEMS) mass sensors based on film bulk acoustic resonator (FBAR) technology. Their products, fabricated on silicon wafers, measure mass down to the femtogram range and temperature with a resolution of 0.2°C, making them suitable for thin film metrology, particulate monitoring, and gas detection applications.
Bond180
Seed Round in 2020
Bond180 Limited is a fintech company based in London, United Kingdom, specializing in technology solutions for the debt capital markets. Founded in 2019, the company develops a digital platform that includes a demand management system (DMS) designed to enhance the market-facing activities of institutional investors through data and analytics. Additionally, Bond180 offers 180Match, a reverse enquiry engine that facilitates communication between investors and the sell-side, and an issue administration network (IAN) that provides digital asset issuance and administration services. The company's focus is on enabling institutional investors to efficiently source assets and identify value in primary markets.
Colorifix
Series A in 2020
Colorifix is a biotechnology company that pioneers biological methods for textile dyeing. It converts agricultural by-products into colorants suitable for textiles, eliminating harsh chemicals and significantly reducing water consumption.
PharmEnable
Seed Round in 2020
PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that specializes in the design of small molecule drugs through the integration of medicinal chemistry and artificial intelligence computational methods. Established in 2016, the company has created a rapid and cost-effective approach to identify superior chemical starting points, thereby facilitating the discovery of essential new medicines.
Qkine
Series A in 2020
Founded in 2016, Qkine is a biotechnology company based in Cambridge, UK. It specializes in manufacturing high-purity, animal-free growth factors, cytokines, and other complex proteins for life science applications, including stem cell culture, organoid research, and regenerative medicine.
Flusso
Series A in 2020
Flusso Ltd, established in 2016 and headquartered in Cambridge, United Kingdom, specializes in the development and manufacturing of sensor solutions tailored to various industries. The company produces mass flow and air velocity sensors, leveraging proprietary technology to meet specific application needs.
Xampla
Seed Round in 2020
Founded in 2018, Xampla develops plant-based materials derived from pea protein to replace microplastics. Its product range includes microcapsules for homecare and personal care products, films, coatings, and single-use plastics for packaging applications.
Porotech
Seed Round in 2020
Porotech is a Cambridge University spin-out focused on developing wide-bandgap compound gallium nitride (GaN) semiconductors. It aims to revolutionize the electronics industry by applying advanced material technologies to unlock GaN's full potential, enabling more efficient light-emitting diodes and other electronic devices.
Kalium Health
Seed Round in 2020
Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.
AudioTelligence
Series A in 2020
AudioTelligence Ltd is a company based in Cambridge, United Kingdom, specializing in advanced audio processing technology. Founded in 2017, AudioTelligence focuses on developing software that enhances the clarity and intelligibility of audio captured from multiple microphones, addressing the challenges posed by loud background noise in conversations. The company employs a data-driven technique known as blind audio signal separation, which significantly outperforms traditional methods such as beamforming and deep neural networks. This innovative technology aims to improve automatic speech recognition (ASR) systems, enabling businesses to provide clearer and more understandable speech for both users and voice-activated devices.
Tenyks
Pre Seed Round in 2020
Tenyks is a Cambridge University spin-out developing an MLOps monitoring and validation platform for computer vision data. It helps machine learning engineers understand and fix algorithm issues, enhancing software reliability.
Cambridge Energy Partners
Seed Round in 2020
Cambridge Energy Partners is a manufacturer of mobile solar trackers for the global commercial and industrial sector. Their trackers look and perform like traditional solar when installed, but arrive at site in prefabricated units, ready for fast deployment and connection (4x faster than traditional installations). Their product is a truly scalable mobile solar tracker, and offers users 'big solar' quality, while also reducing stranded asset risk - enabling the owner to deploy the asset multiple times over its 25-year useful life.
Spirea
Pre Seed Round in 2019
Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.
Porotech
Seed Round in 2019
Porotech is a Cambridge University spin-out focused on developing wide-bandgap compound gallium nitride (GaN) semiconductors. It aims to revolutionize the electronics industry by applying advanced material technologies to unlock GaN's full potential, enabling more efficient light-emitting diodes and other electronic devices.
Nu Quantum
Pre Seed Round in 2019
Nu Quantum Ltd is a company focused on developing quantum photonics hardware and quantum networking infrastructure to enhance the capabilities of quantum computing. Established in 2018 and based in Cambridge, United Kingdom, the company specializes in creating photon sources, detectors, and systems for quantum cryptography. Nu Quantum's innovations include nano-engineered materials for the generation of light at the quantum level and ultra-sensitive light detection systems. The company aims to establish the necessary infrastructure for interconnecting quantum computing cores into large distributed clusters, which is essential for scaling quantum computers. By developing full hardware solutions, including high-speed network interfaces and photonic switching fabrics, Nu Quantum seeks to facilitate the creation of entangled qubit networks. The company collaborates with leading quantum computing firms, governments, and research institutions to bring its advanced technologies to market, focusing on secure cryptographic key exchange and the future of information processing.
Bond180
Pre Seed Round in 2019
Bond180 Limited is a fintech company based in London, United Kingdom, specializing in technology solutions for the debt capital markets. Founded in 2019, the company develops a digital platform that includes a demand management system (DMS) designed to enhance the market-facing activities of institutional investors through data and analytics. Additionally, Bond180 offers 180Match, a reverse enquiry engine that facilitates communication between investors and the sell-side, and an issue administration network (IAN) that provides digital asset issuance and administration services. The company's focus is on enabling institutional investors to efficiently source assets and identify value in primary markets.
PredictImmune
Series B in 2019
PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.
Paragraf
Series A in 2019
Paragraf is a UK-based company specializing in graphene technology. Established in 2015, it focuses on developing high-purity graphene products for commercial applications, particularly in electronics. The company produces graphene electronic devices and sensors using contamination-free technology.
Riverlane
Seed Round in 2019
Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.
Qkine
Seed Round in 2019
Founded in 2016, Qkine is a biotechnology company based in Cambridge, UK. It specializes in manufacturing high-purity, animal-free growth factors, cytokines, and other complex proteins for life science applications, including stem cell culture, organoid research, and regenerative medicine.
PolyProx
Seed Round in 2019
PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.
Sano Genetics
Seed Round in 2019
Sano Genetics is a health technology company that operates a user-centered genetic data-sharing platform. The platform enables researchers to analyze data provided with user consent and to recruit for studies and clinical trials based on participants’ genetic and health information. It provides access to research on genetics and genetic diseases and supports programs that study the genetics of various human traits. The company connects individuals with researchers through its platform, supporting both common and rare disease research and enabling dynamic, health and genetic data sets to advance personalized medicine. Founded in 2017 and based in Cambridge, United Kingdom, Sano Genetics aims to empower participants to contribute their genetic and health data to scientific studies, facilitating collaboration and enabling new approaches to diagnosis and treatment.
Morphogen-IX
Series B in 2018
Founded in 2015 and headquartered in Cambridge, UK, Morphogen-IX is a biotechnology company focused on developing novel therapies for pulmonary arterial hypertension (PAH). The company's core expertise lies in bone morphogenetic proteins (BMPs), with a particular emphasis on BMP9 and BMP10. Its semi-virtual model combines an experienced team of drug discovery professionals with outsourced development programs, aiming to maximize capital efficiency while maintaining high-quality research.
Colorifix
Series A in 2018
Colorifix is a biotechnology company that pioneers biological methods for textile dyeing. It converts agricultural by-products into colorants suitable for textiles, eliminating harsh chemicals and significantly reducing water consumption.
Healthera
Series A in 2018
Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.
Silicon Microgravity
Venture Round in 2018
Silicon Microgravity is a Cambridge, United Kingdom based sensor technology company that develops microelectromechanical systems for oil and gas reservoir surveillance and other applications. Its gravity sensors deliver high-sensitivity gravity data and ultra-low-frequency seismic data from boreholes, enabling precise density measurements deep in reservoirs and real-time reservoir management. The technology originated as a Cambridge University spin-out, developed with support from BP and Innovate UK, and has broader uses in navigation and stabilization of intelligent systems across commercial, industrial, and military sectors. The company aims to improve efficiency, reduce costs, and support safety and environmental goals in hydrocarbon production.
Sorex Sensors
Seed Round in 2018
Sorex Sensors designs and manufactures high-sensitivity micro-electro-mechanical system (MEMS) mass sensors based on film bulk acoustic resonator (FBAR) technology. Their products, fabricated on silicon wafers, measure mass down to the femtogram range and temperature with a resolution of 0.2°C, making them suitable for thin film metrology, particulate monitoring, and gas detection applications.
Cambridge Touch Technologies
Series A in 2018
Cambridge Touch Technologies develops piezoelectric-based 3D touch technology for smartphones, tablets, automotive, and industrial applications. Its UltraTouch platform combines proprietary artificial intelligence with sophisticated signal processing and a piezoelectric force film to deliver an all-in-one touch and force sensor architecture that offers advanced functionality at lower cost and scales to curved and foldable device sizes. The company targets pressure sensing and 3D touch to enhance interaction in consumer electronics and industrial applications.
PhoreMost
Series A in 2018
PhoreMost is a UK-based drug discovery company specializing in identifying new druggable targets for cancer and other diseases. Established in 2014, it develops Site-Seeker, a platform that systematically uncovers druggable sites in the human genome and links them to useful therapeutic functions in live cells.
Qkine
Seed Round in 2018
Founded in 2016, Qkine is a biotechnology company based in Cambridge, UK. It specializes in manufacturing high-purity, animal-free growth factors, cytokines, and other complex proteins for life science applications, including stem cell culture, organoid research, and regenerative medicine.
Paragraf
Seed Round in 2018
Paragraf is a UK-based company specializing in graphene technology. Established in 2015, it focuses on developing high-purity graphene products for commercial applications, particularly in electronics. The company produces graphene electronic devices and sensors using contamination-free technology.
Cytora
Series A in 2017
Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.
PredictImmune
Series A in 2017
PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.
Z Factor
Series A in 2017
Z Factor Limited is a drug discovery company established in 2015 with a focus on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company is dedicated to designing innovative treatments that address the misfolding of the Z variant of alpha-1-antitrypsin. This condition presents significant medical challenges, and current treatment options are largely restricted to lung or liver transplantation and augmentation therapy. By targeting the underlying causes of the disease, Z Factor aims to fulfill a critical unmet medical need in the field of respiratory and liver health.
Focal Point Positioning
Series B in 2017
Focal Point Positioning Ltd. is a technology company based in Cambridge, United Kingdom, that specializes in advanced positioning, navigation, and timing solutions. Founded in 2015, it leverages smartphone-based sensor fusion, machine learning, and signal processing to offer satellite positioning capabilities in previously unreachable areas. The company has developed two core products, S-GNSS and D-Tail, which enhance the sensitivity and accuracy of GPS receivers and utilize existing smartphone sensors for precise three-dimensional tracking. Focal Point serves a diverse range of sectors, including defense, security, aerospace, autonomy, telecommunications, retail, logistics, and emergency services, addressing challenges in GNSS and GPS-denied environments. The company is led by Dr. Ramsey Faragher, a recognized expert in the field, who has a distinguished background that includes significant contributions to multi-sensor positioning systems and advanced navigation technologies for various applications, including unmanned vehicles and space exploration.
Cytora
Series A in 2017
Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.
Polypharmakos
Series A in 2017
Founded in 2016, Polypharmakos is a UK-based company dedicated to discovering and developing new antimicrobials from plants, fungi, and other natural product sources. Its mission is to address the global crisis of antimicrobial resistance.
Cambridge Touch Technologies
Series A in 2016
Cambridge Touch Technologies develops piezoelectric-based 3D touch technology for smartphones, tablets, automotive, and industrial applications. Its UltraTouch platform combines proprietary artificial intelligence with sophisticated signal processing and a piezoelectric force film to deliver an all-in-one touch and force sensor architecture that offers advanced functionality at lower cost and scales to curved and foldable device sizes. The company targets pressure sensing and 3D touch to enhance interaction in consumer electronics and industrial applications.
Carrick Therapeutics
Series A in 2016
Founded in 2015, Carrick Therapeutics is a biopharmaceutical company based in Dublin, Ireland. It specializes in developing innovative cancer therapeutics that target molecular pathways driving aggressive and resistant forms of cancer, aiming to transform cancer treatment.
PervasID
Series A in 2016
Founded in 2011, PervasID specializes in developing wide area RFID systems that offer location capabilities based on the EPC Class1 Gen2 standard. The company's technology enables accurate tracking of goods and assets across various industries.
Fluidic Analytics
Series B in 2016
Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.
Cambridge Innovation Capital
Venture Round in 2016
Cambridge Innovation Capital is a Cambridge-based venture capital firm that specializes in early-stage and growth investments in life sciences and technology. It focuses on companies affiliated with the University of Cambridge or the Cambridge Cluster and seeks to back innovations in therapeutics, medtech and diagnostics, digital health, genomics and proteomics, artificial intelligence, the Internet of Things, quantum technologies, and autonomous systems. The organization provides long-term equity capital to help portfolio companies bridge development stages and scale, with a strong emphasis on opportunities arising from the Cambridge ecosystem. Since its founding in 2013, Cambridge Innovation Capital has established itself as a leading investor within that community, leveraging close ties to academia to access high-potential deep-tech opportunities.
Healthera
Seed Round in 2016
Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.
8power
Seed Round in 2016
8power Limited develops wireless sensor technology for industrial plant applications. Its systems monitor machine conditions across thousands of remote assets in sectors like automotive, civil engineering, and utilities.
Psyomics
Series A in 2016
Psyomics specializes in the development of proteomic diagnostics aimed at improving early diagnosis and treatment outcomes for individuals with neuropsychiatric disorders. The company offers web-based assessment triage designed to facilitate diagnostic and pathway prediction for mental health conditions. By integrating digital profiling with cutting-edge biological research, Psyomics enhances diagnostic accuracy and supports primary care practitioners in effectively managing their patients' mental health needs. This innovative approach digitally replicates a psychiatric assessment at the initial point of contact, thereby enabling patients to achieve better recovery outcomes from mental health disorders.
DefiniGEN Limited
Series B in 2016
DefiniGEN specializes in providing human cell products for life science and drug discovery sectors. Its offerings include specialized hepatocytes and pancreatic cells for predictive toxicology, diabetes research, and disease modeling. The company serves pharmaceutical companies by offering custom cell production services and contract services such as Def-PANC diabetes compound profiling.
ROADMap Systems
Series A in 2016
ROADMap Systems Limited is a technology company based in Cambridge, United Kingdom, specializing in wavelength selective switch (WSS) technology for fiber optic communication networks. Founded in 2013, the company addresses the growing demands of network operators by providing solutions that enable reconfigurable optical add/drop multiplexers (ROADMs). These advanced switches are designed to handle the increasing capacity required for high-speed internet data, specifically accommodating next-generation data rates of 400 Gbps. ROADMap Systems leverages four patents licensed from the Cambridge Centre for Advanced Photonics and Electronics to offer telecom and datacom applications that tackle challenges related to data rates, fiber management, power requirements, and network costs. By focusing on highly flexible optical switching capabilities, the company aims to meet the evolving needs of the telecommunications industry.
Cambridge Epigenetix
Series B in 2016
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.
Morphogen-IX
Series A in 2016
Founded in 2015 and headquartered in Cambridge, UK, Morphogen-IX is a biotechnology company focused on developing novel therapies for pulmonary arterial hypertension (PAH). The company's core expertise lies in bone morphogenetic proteins (BMPs), with a particular emphasis on BMP9 and BMP10. Its semi-virtual model combines an experienced team of drug discovery professionals with outsourced development programs, aiming to maximize capital efficiency while maintaining high-quality research.
Silicon Microgravity
Seed Round in 2016
Silicon Microgravity is a Cambridge, United Kingdom based sensor technology company that develops microelectromechanical systems for oil and gas reservoir surveillance and other applications. Its gravity sensors deliver high-sensitivity gravity data and ultra-low-frequency seismic data from boreholes, enabling precise density measurements deep in reservoirs and real-time reservoir management. The technology originated as a Cambridge University spin-out, developed with support from BP and Innovate UK, and has broader uses in navigation and stabilization of intelligent systems across commercial, industrial, and military sectors. The company aims to improve efficiency, reduce costs, and support safety and environmental goals in hydrocarbon production.
Cytora
Seed Round in 2015
Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.
Quethera
Seed Round in 2015
Quethera Limited is a biotechnology company based in Canterbury, United Kingdom, focused on developing gene therapy treatments for glaucoma and other ophthalmic diseases. Established in 2013, the company aims to address progressive visual loss associated with these conditions, particularly in patients experiencing accelerated deterioration of their visual fields. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that assess the efficacy and safety of its innovative therapies. With a strong foundation in gene therapeutic design and development, Quethera is advancing its pipeline from preclinical testing into clinical development, striving to provide effective treatment solutions for common blinding eye diseases. As of 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.
Focal Point Positioning
Seed Round in 2015
Focal Point Positioning Ltd. is a technology company based in Cambridge, United Kingdom, that specializes in advanced positioning, navigation, and timing solutions. Founded in 2015, it leverages smartphone-based sensor fusion, machine learning, and signal processing to offer satellite positioning capabilities in previously unreachable areas. The company has developed two core products, S-GNSS and D-Tail, which enhance the sensitivity and accuracy of GPS receivers and utilize existing smartphone sensors for precise three-dimensional tracking. Focal Point serves a diverse range of sectors, including defense, security, aerospace, autonomy, telecommunications, retail, logistics, and emergency services, addressing challenges in GNSS and GPS-denied environments. The company is led by Dr. Ramsey Faragher, a recognized expert in the field, who has a distinguished background that includes significant contributions to multi-sensor positioning systems and advanced navigation technologies for various applications, including unmanned vehicles and space exploration.
Reduse
Series A in 2015
Reduse Limited is a company based in Cambridge, United Kingdom, that specializes in providing print removal services from paper using laser technology. Founded in 2015 by David Leal-Ayala, Hidde-Jan Lemstra, and Stuart Evans, Reduse aims to offer innovative solutions for the efficient recycling and repurposing of printed materials. The company focuses on sustainability by enabling the reuse of paper, thereby contributing to environmental conservation efforts.
Fluidic Analytics
Series A in 2014
Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.
Cambridge Epigenetix
Series A in 2014
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.